ISSN:
1436-2813
Keywords:
rIL-2
;
malignant pleural effusion
;
intrapleural administration
;
lymphokine-activated killer activity
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Recombinant IL-2 (rIL-2) was administered intra-pleurally according to an original protocol to 11 patients with malignant pleural effusion, 7 of whom suffered from breast cancer and 4 from esophageal cancer. The pleural effusions either disappeared or decreased roentgenographically, and malignant cells disappeared from all 13 pleural cavities in the 11 patients, confirming the validity of this therapy to be 100%. The mean survival time from the initial administration of rIL-2 was 15.9 months. We ensured that the concentration of IL-2 in the effusion was maintained at a high level for a sufficient period of time, and that the lymphokine-activated killer (LAK) activity of lymphocytes in the effusion was augmented. Fever, eosinophilia, and a transient increase in the pleural effusion were the main side effects, but the symptoms were temporary and not serious. The results of this study therefore suggest the efficacy of intrapleural rIL-2 for patients with malignant pleural effusion.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00309093
Permalink